HARARE – Zimbabwe Stock Exchange (ZSE)-listed pharmaceuticals manufacturer Medtech is facing an uncertain future should a strategic transaction fail to go through this year. The group’s chairperson, Rose Mazula, yesterday said Medtech’s future lies in the anticipated transaction, which will see the group place about 70 percent in its medical unit with a potential investor…
To access this content, please purchase a subscription by clicking the button below and select a package of your choice!
Subscriptions